Nicole W. Simons
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nicole W. Simons has a total of 292 co-authors. Here are the top co-authors by number of shared publications:
Seunghee Kim-Schulze
Icahn School of Medicine at Mount Sinai, New York, USA
4 shared publicationsAlexander W. Charney
Icahn School of Medicine at Mount Sinai
3 shared publications- Alexander William Charney
Icahn School of Medicine at Mount Sinai
3 shared publications - Diane Marie Del Valle
Icahn School of Medicine at Mount Sinai 7 Tisch Cancer Institute New York, New York
3 shared publications Miriam Merad
Affiliation Precision Immunology Institute, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York city, New York, United States of America
3 shared publications- Ryan C. Thompson
Icahn School of Medicine at Mount Sinai
3 shared publications
Latest Publications
- Open Access
- 12 October 2026
- Published by Elsevier in Biological Psychiatry
Development of a messenger RNA therapy for schizophrenia
- 12 October 2026
- Published by Elsevier in Biological Psychiatry
Open AccessDevelopment of a messenger RNA therapy for schizophrenia
- Open Access
- 9 September 2026
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 56, e265
Stakeholder perspectives on artificial intelligence in schizophrenia care
Background: Artificial intelligence (AI) is explored as a tool to expand access to mental health care, offering support and self-disclosure. To date, the perspectives of individuals with schizophrenia on AI have been absent from the medical literature. This exploratory study represents an effort to report schizophrenia patient perspectives on AI chatbots through a focus group. Methods: We conducted an exploratory, cross-sectional, qualitative study using semi-structured focus groups at a large academic health center in New York City. Participants included patients with schizophrenia spectrum disorders ( n = 17), caregivers ( n = 7), and providers ( n = 4). Discussions explored familiarity with AI, privacy, and perceived utility of a hypothetical AI companion tool. Transcripts were analyzed using thematic analysis. Results: Five themes were identified in this exploratory analysis: (1) ‘Available When No One Else Is’, reflecting participants’ recognition of AI as a potentially accessible source of between-visit support; (2) ‘What Would It Do?’ capturing uncertainty about AI’s role; (3) ‘How Can I Trust It?’ highlighting trust as the central barrier, shaped by privacy concerns and schizophrenia-specific vulnerabilities; (4) ‘A Tool, Not a Therapist’, emphasizing that AI was acceptable only as a supplement to, not a replacement for, human care; and (5) ‘Keep It Low-Risk’, describing the narrow range of acceptable use cases, limited to supportive functions. Conclusions: These exploratory findings suggest that AI is perceived as both a promising adjunct to care and a potential risk in schizophrenia. Implementation should emphasize transparency, trust, and clear boundaries, with AI designed to support, not replace, existing care.
- 9 September 2026
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 56, e265
Open AccessStakeholder perspectives on artificial intelligence in schizophrenia care
Background: Artificial intelligence (AI) is explored as a tool to expand access to mental health care, offering support and self-disclosure. To date, the perspectives of individuals with schizophrenia on AI have been absent from the medical literature. This exploratory study represents an effort to report schizophrenia patient perspectives on AI chatbots through a focus group. Methods: We conducted an exploratory, cross-sectional, qualitative study using semi-structured focus groups at a large academic health center in New York City. Participants included patients with schizophrenia spectrum disorders ( n = 17), caregivers ( n = 7), and providers ( n = 4). Discussions explored familiarity with AI, privacy, and perceived utility of a hypothetical AI companion tool. Transcripts were analyzed using thematic analysis. Results: Five themes were identified in this exploratory analysis: (1) ‘Available When No One Else Is’, reflecting participants’ recognition of AI as a potentially accessible source of between-visit support; (2) ‘What Would It Do?’ capturing uncertainty about AI’s role; (3) ‘How Can I Trust It?’ highlighting trust as the central barrier, shaped by privacy concerns and schizophrenia-specific vulnerabilities; (4) ‘A Tool, Not a Therapist’, emphasizing that AI was acceptable only as a supplement to, not a replacement for, human care; and (5) ‘Keep It Low-Risk’, describing the narrow range of acceptable use cases, limited to supportive functions. Conclusions: These exploratory findings suggest that AI is perceived as both a promising adjunct to care and a potential risk in schizophrenia. Implementation should emphasize transparency, trust, and clear boundaries, with AI designed to support, not replace, existing care.
- Open Access
- 8 December 2022
- Published by Springer Nature in Nature Medicine
- Vol. 29 (1) , 236-246
Molecular states during acute COVID-19 reveal distinct etiologies of long-term sequelae
Post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are debilitating, clinically heterogeneous and of unknown molecular etiology. A transcriptome-wide investigation was performed in 165 acutely infected hospitalized individuals who were followed clinically into the post-acute period. Distinct gene expression signatures of post-acute sequelae were already present in whole blood during acute infection, with innate and adaptive immune cells implicated in different symptoms. Two clusters of sequelae exhibited divergent plasma-cell-associated gene expression patterns. In one cluster, sequelae associated with higher expression of immunoglobulin-related genes in an anti-spike antibody titer-dependent manner. In the other, sequelae associated independently of these titers with lower expression of immunoglobulin-related genes, indicating lower non-specific antibody production in individuals with these sequelae. This relationship between lower total immunoglobulins and sequelae was validated in an external cohort. Altogether, multiple etiologies of post-acute sequelae were already detectable during SARS-CoV-2 infection, directly linking these sequelae with the acute host response to the virus and providing early insights into their development.
- 8 December 2022
- Published by Springer Nature in Nature Medicine
- Vol. 29 (1) , 236-246
Open AccessMolecular states during acute COVID-19 reveal distinct etiologies of long-term sequelae
Post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are debilitating, clinically heterogeneous and of unknown molecular etiology. A transcriptome-wide investigation was performed in 165 acutely infected hospitalized individuals who were followed clinically into the post-acute period. Distinct gene expression signatures of post-acute sequelae were already present in whole blood during acute infection, with innate and adaptive immune cells implicated in different symptoms. Two clusters of sequelae exhibited divergent plasma-cell-associated gene expression patterns. In one cluster, sequelae associated with higher expression of immunoglobulin-related genes in an anti-spike antibody titer-dependent manner. In the other, sequelae associated independently of these titers with lower expression of immunoglobulin-related genes, indicating lower non-specific antibody production in individuals with these sequelae. This relationship between lower total immunoglobulins and sequelae was validated in an external cohort. Altogether, multiple etiologies of post-acute sequelae were already detectable during SARS-CoV-2 infection, directly linking these sequelae with the acute host response to the virus and providing early insights into their development.
- Open Access
- 3 November 2022
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 18 (11) , e1010367
Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative
Host genetics is a key determinant of COVID-19 outcomes. Previously, the COVID-19 Host Genetics Initiative genome-wide association study used common variants to identify multiple loci associated with COVID-19 outcomes. However, variants with the largest impact on COVID-19 outcomes are expected to be rare in the population. Hence, studying rare variants may provide additional insights into disease susceptibility and pathogenesis, thereby informing therapeutics development. Here, we combined whole-exome and whole-genome sequencing from 21 cohorts across 12 countries and performed rare variant exome-wide burden analyses for COVID-19 outcomes. In an analysis of 5,085 severe disease cases and 571,737 controls, we observed that carrying a rare deleterious variant in the SARS-CoV-2 sensor toll-like receptor TLR7 (on chromosome X) was associated with a 5.3-fold increase in severe disease (95% CI: 2.75–10.05, p = 5.41x10-7). This association was consistent across sexes. These results further support TLR7 as a genetic determinant of severe disease and suggest that larger studies on rare variants influencing COVID-19 outcomes could provide additional insights.
- 3 November 2022
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 18 (11) , e1010367
Open AccessExome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative
Host genetics is a key determinant of COVID-19 outcomes. Previously, the COVID-19 Host Genetics Initiative genome-wide association study used common variants to identify multiple loci associated with COVID-19 outcomes. However, variants with the largest impact on COVID-19 outcomes are expected to be rare in the population. Hence, studying rare variants may provide additional insights into disease susceptibility and pathogenesis, thereby informing therapeutics development. Here, we combined whole-exome and whole-genome sequencing from 21 cohorts across 12 countries and performed rare variant exome-wide burden analyses for COVID-19 outcomes. In an analysis of 5,085 severe disease cases and 571,737 controls, we observed that carrying a rare deleterious variant in the SARS-CoV-2 sensor toll-like receptor TLR7 (on chromosome X) was associated with a 5.3-fold increase in severe disease (95% CI: 2.75–10.05, p = 5.41x10-7). This association was consistent across sexes. These results further support TLR7 as a genetic determinant of severe disease and suggest that larger studies on rare variants influencing COVID-19 outcomes could provide additional insights.
- Open Access
- 14 September 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (662) , eabn5168
A shift in lung macrophage composition is associated with COVID-19 severity and recovery
Although it has been more than 2 years since the start of the coronavirus disease 2019 (COVID-19) pandemic, COVID-19 continues to be a worldwide health crisis. Despite the development of preventive vaccines, therapies to treat COVID-19 and other inflammatory diseases remain a major unmet need in medicine. Our study sought to identify drivers of disease severity and mortality to develop tailored immunotherapy strategies to halt disease progression. We assembled the Mount Sinai COVID-19 Biobank, which was composed of almost 600 hospitalized patients followed longitudinally through the peak of the pandemic in 2020. Moderate disease and survival were associated with a stronger antigen presentation and effector T cell signature. In contrast, severe disease and death were associated with an altered antigen presentation signature, increased numbers of inflammatory immature myeloid cells, and extrafollicular activated B cells that have been previously associated with autoantibody formation. In severely ill patients with COVID-19, lung tissue–resident alveolar macrophages not only were drastically depleted but also had an altered antigen presentation signature, which coincided with an influx of inflammatory monocytes and monocyte-derived macrophages. In addition, we found that the size of the alveolar macrophage pool correlated with patient outcome and that alveolar macrophage numbers and functionality were restored to homeostasis in patients who recovered from COVID-19. These data suggest that local and systemic myeloid cell dysregulation are drivers of COVID-19 severity and modulation of alveolar macrophage numbers and activity in the lung may be a viable therapeutic strategy for the treatment of critical inflammatory lung diseases.
- 14 September 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (662) , eabn5168
Open AccessA shift in lung macrophage composition is associated with COVID-19 severity and recovery
Although it has been more than 2 years since the start of the coronavirus disease 2019 (COVID-19) pandemic, COVID-19 continues to be a worldwide health crisis. Despite the development of preventive vaccines, therapies to treat COVID-19 and other inflammatory diseases remain a major unmet need in medicine. Our study sought to identify drivers of disease severity and mortality to develop tailored immunotherapy strategies to halt disease progression. We assembled the Mount Sinai COVID-19 Biobank, which was composed of almost 600 hospitalized patients followed longitudinally through the peak of the pandemic in 2020. Moderate disease and survival were associated with a stronger antigen presentation and effector T cell signature. In contrast, severe disease and death were associated with an altered antigen presentation signature, increased numbers of inflammatory immature myeloid cells, and extrafollicular activated B cells that have been previously associated with autoantibody formation. In severely ill patients with COVID-19, lung tissue–resident alveolar macrophages not only were drastically depleted but also had an altered antigen presentation signature, which coincided with an influx of inflammatory monocytes and monocyte-derived macrophages. In addition, we found that the size of the alveolar macrophage pool correlated with patient outcome and that alveolar macrophage numbers and functionality were restored to homeostasis in patients who recovered from COVID-19. These data suggest that local and systemic myeloid cell dysregulation are drivers of COVID-19 severity and modulation of alveolar macrophage numbers and activity in the lung may be a viable therapeutic strategy for the treatment of critical inflammatory lung diseases.
- Open Access
Quantitative chest computed tomography combined with plasma cytokines predict outcomes in COVID-19 patients
- Top Cited Papers
Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C)